AAPS PharmSciTech

, Volume 16, Issue 1, pp 202–216 | Cite as

Quality-by-Design III: Application of Near-Infrared Spectroscopy to Monitor Roller Compaction In-process and Product Quality Attributes of Immediate Release Tablets

  • Ravikanth Kona
  • Raafat M. Fahmy
  • Gregg Claycamp
  • James E. Polli
  • Marilyn Martinez
  • Stephen W. Hoag
Research Article Theme: Quality by Design: Case Studies and Scientific Foundations

Abstract

The objective of this study is to use near-infrared spectroscopy (NIRS) coupled with multivariate chemometric models to monitor granule and tablet quality attributes in the formulation development and manufacturing of ciprofloxacin hydrochloride (CIP) immediate release tablets. Critical roller compaction process parameters, compression force (CFt), and formulation variables identified from our earlier studies were evaluated in more detail. Multivariate principal component analysis (PCA) and partial least square (PLS) models were developed during the development stage and used as a control tool to predict the quality of granules and tablets. Validated models were used to monitor and control batches manufactured at different sites to assess their robustness to change. The results showed that roll pressure (RP) and CFt played a critical role in the quality of the granules and the finished product within the range tested. Replacing binder source did not statistically influence the quality attributes of the granules and tablets. However, lubricant type has significantly impacted the granule size. Blend uniformity, crushing force, disintegration time during the manufacturing was predicted using validated PLS regression models with acceptable standard error of prediction (SEP) values, whereas the models resulted in higher SEP for batches obtained from different manufacturing site. From this study, we were able to identify critical factors which could impact the quality attributes of the CIP IR tablets. In summary, we demonstrated the ability of near-infrared spectroscopy coupled with chemometrics as a powerful tool to monitor critical quality attributes (CQA) identified during formulation development.

KEY WORDS

chemometrics crushing force disintegration near-infrared spectroscopy partial least square principal component analysis quality by design roller compaction 

References

  1. 1.
    Teng Y, Qiu Z, Wen H. Systematical approach of formulation and process development using roller compaction. Eur J Pharm Biopharm. 2009;73(2):219–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Malkowska S, Khan KA. Effect of re-conpression on the properties of tablets prepared by dry granulation. Drug Dev Ind Pharm. 1983;9(3):331–47.CrossRefGoogle Scholar
  3. 3.
    Sun C, Himmelspach M. Reduced tabletability of roller compacted granules as a result of granule size enlargement. J Pharm Sci. 2006;95(1):200–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Roberts RJ, Rowe RC. The effect of punch velocity on the compaction of a variety of materials. J Pharm Pharmacol. 1985;37(6):377–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Ruegger CE, Celik M. The effect of compression and decompression speed on the mechanical strength of compacts. Pharm Dev Technol. 2000;5(4):485–94.PubMedCrossRefGoogle Scholar
  6. 6.
    Bacher C, Olsen PM, Bertelsen P, Kristensen J, Sonnergaard JM. Improving the compaction properties of roller compacted calcium carbonate. Int J Pharm. 2007;342(1–2):115–23.PubMedCrossRefGoogle Scholar
  7. 7.
    Inghelbrecht S, Remon JP. Roller compaction and tableting of microcrystalline cellulose/drug mixtures. Int J Pharm. 1998;161(2):215–24.CrossRefGoogle Scholar
  8. 8.
    Daugherity PD, Chu JH. Investigation of serrated roll surface differences on ribbon thickness during roller compaction. Pharm Dev Technol. 2007;12(6):603–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Tabasi S, Fahmy R, Bensley D, O’Brien C, Hoag S. Quality by design, part I: application of NIR spectroscopy to monitor tablet manufacturing process. J Pharm Sci. 2008;97(9):4040–51.PubMedCrossRefGoogle Scholar
  10. 10.
    ICH. Q8(R2): Pharmaceutical development. Part I: pharmaceutical development, and part II: annex to pharmaceutical development. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf (2009).
  11. 11.
    Cantor S, Hoag S, Ellison C, Khan M, Lyon R. NIR spectroscopy applications in the development of a compacted multiparticulate system for modified release. AAPS PharmSciTech. 2011;12(1):262–78.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Tabasi S, Fahmy R, Bensley D, O’Brien C, Hoag S. Quality by design, part II: application of NIR spectroscopy to monitor the coating process for a pharmaceutical sustained release product. J Pharm Sci. 2008;97(9):4052–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Tatavarti A, Fahmy R, Wu H, Hussain A, Marnane W, Bensley D, et al. Assessment of NIR spectroscopy for nondestructive analysis of physical and chemical attributes of sulfamethazine bolus dosage forms. AAPS PharmSciTech. 2005;6(1):E91–9.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Gupta A, Peck G, Miller R, Morris K. Influence of ambient moisture on the compaction behavior of microcrystalline cellulose powder undergoing uni-axial compression and roller-compaction: a comparative study using near-infrared spectroscopy. J Pharm Sci. 2005;94(10):2301–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Gupta A, Peck G, Miller R, Morris K. Real-time near-infrared monitoring of content uniformity, moisture content, compact density, tensile strength, and Young’s modulus of roller compacted powder blends. J Pharm Sci. 2005;94(7):1589–97.PubMedCrossRefGoogle Scholar
  16. 16.
    Soh J, Boersen N, Carvajal T, Morris K, Peck G, Pinal R. Importance of raw material attributes for modeling ribbon and granule properties in roller compaction: multivariate analysis on roll gap and NIR spectral slope as process critical control parameters. J Pharm Innov. 2007;2:106–24.CrossRefGoogle Scholar
  17. 17.
  18. 18.
  19. 19.
    Fahmy R, Kona R, Dandu R, Xie W, Claycamp G, Hoag S. Quality by design I: application of failure mode effect analysis (FMEA) and Plackett-Burman design of experiments in the identification of “main factors” in the formulation and process design space for roller-compacted ciprofloxacin hydrochloride immediate-release tablets. AAPS PharmSciTech. 2012;13(4):1243–54.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Claycamp G, Kona R, Fahmy R, Polli J, Martinez M, Hoag S. Quality-by-design II: application of quantitative risk analysis to the formulation of ciprofloxacin tablets. in preparation for PharmSciTech. 2012.Google Scholar
  21. 21.
    Desai D, Rinaldi F, Kothari S, Paruchuri S, Li D, Lai M, et al. Effect of hydroxypropyl cellulose (HPC) on dissolution rate of hydrochlorothiazide tablets. Int J Pharm. 2006;308(1–2):40–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S, et al. Biowaiver monographs for immediate release solid oral dosage forms: Ciprofloxacin hydrochloride. J Pharm Sci. 2011;100(1):22–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Lim H, Dave V, Kidder L, Neil Lewis E, Fahmy R, Hoag S. Assessment of the critical factors affecting the porosity of roller compacted ribbons and the feasibility of using NIR chemical imaging to evaluate the porosity distribution. Int J Pharm. 2011;410(1–2):1–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Okoye P. Lubrication of direct-compressible blends. Pharm Technol. 2007;31(9):116.Google Scholar
  25. 25.
    Dave V, Fahmy R, Bensley D, Hoag S. Eudragit(®) RS PO/RL PO as rate-controlling matrix-formers via roller compaction: influence of formulation and process variables on functional attributes of granules and tablets. Drug Dev Ind Pharm. 2012.Google Scholar
  26. 26.
    Dave V, Fahmy R, Hoag SW. Roller Compaction of Eudragit polymers Part 2. Drug Dev Ind Pharm. 2011; Submitted to Drug Dev Ind Pharm.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2014

Authors and Affiliations

  • Ravikanth Kona
    • 1
  • Raafat M. Fahmy
    • 2
  • Gregg Claycamp
    • 2
  • James E. Polli
    • 1
  • Marilyn Martinez
    • 2
  • Stephen W. Hoag
    • 1
  1. 1.School of PharmacyUniversity of MarylandBaltimoreUSA
  2. 2.Office of New Animal Drug EvaluationCenter for Veterinary Medicine, FDARockvilleUSA

Personalised recommendations